While human validation is lacking, these mechanistic insights suggest that cholinergic and neurotrophin-based therapies may hold dual benefit for intestinal inflammation and comorbid psychiatric manifestations in IBD. This evidence concerns the gene BDNF and inflammatory bowel disease.